Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib has been approved for treatment of advanced ovarian cancer associated with BRCA1 and BRCA2 mutations. BRCA1- and BRCA2-mutated cells, which are homologous recombination (HR) deficient, are hypersensitive to PARPi through the mechanism of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Ding, Xia, Chaudhuri, Arnab Ray, Callen, Elsa, Pang, Yan, Biswas, Kajal, Klarmann, Kimberly D., Martin, Betty K., Burkett, Sandra, Cleveland, Linda, Stauffer, Stacey, Sullivan, Teresa, Dewan, Aashish, Marks, Hanna, Tubbs, Anthony T., Wong, Nancy, Buehler, Eugen, Akagi, Keiko, Martin, Scott E., Keller, Jonathan R., Nussenzweig, André, Sharan, Shyam K.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4979061/
https://ncbi.nlm.nih.gov/pubmed/27498558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ncomms12425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados